Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Relapsing-Remitting Multiple Sclerosis Clinical Trial

— COSTAN  

Official title:

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01706107
• Other study ID #: CAN-TYS-12-10333
• Status: Terminated
• Start date: November 7, 2012
• Est. completion date: October 2, 2015

Study information

• Verified date: May 2024
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of the study is to evaluate the impact of early treatment with Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) participants on their quality of life (QoL) as measured by Multiple Sclerosis Impact Scale-29 (MSIS-29) over 2 years. The secondary objectives of the study are: to evaluate the impact of early treatment with Tysabri in RRMS participants over 2 years on the following: annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), work productivity, quality of life (QoL) by EuroQol 5-Dimension questionnaire (EQ-5D), QoL by Subject Global Assessment of Wellbeing visual analog scale (VAS) and to evaluate clinical disease-free status (relapses, EDSS) over 2 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 73
• Est. completion date: October 2, 2015
• Est. primary completion date: October 2, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Key Inclusion Criteria:

• Ability to understand the purpose and risks of the study and provide signed and dated informed consent.

• Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria).

• Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.

• Must satisfy the approved therapeutic indications for Tysabri as per Product Monograph.

• Must either be treatment naïve or have been treated with disease modifying therapy DMT(s) (such as, but not limited to, Avonex, Betaseron, Rebif, Copaxone, Extavia, Tecfidera and/or Gilenya) for =5 years total prior to date of informed consent.

• Decision to treat with Tysabri must precede enrollment.

Key Exclusion Criteria:

• Any prior treatment with Tysabri.

• Contraindications to treatment with Tysabri as described in the Product Monograph.

• History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.

• History of diagnosis of Primary Progressive Multiple Sclerosis [PPMS] and/or Secondary Progressive Multiple Sclerosis [SPMS].

• Receiving immunomodulatory or immunosuppressive therapy.

• Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).

• Immunocompromised at the time of enrollment.

• Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).

• Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.

• Inability to comply with study requirements.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis

Locations

Country	Name	City	State
Canada	Clinique Neuro-Outaouais	Gatineau	Quebec
Canada	Neuro Rive-Sud	Greenfield Park	Quebec
Canada	Dalhousie MS Research Unit	Halifax	Nova Scotia
Canada	London Health Sciences Centre	London	Ontario
Canada	CHUM - Hopital Notre Dame	Montreal	Quebec
Canada	McGill University - MNI	Montreal	Quebec
Canada	Saint John Regional Hospital	Saint John	New Brunswick
Canada	CHUS - Hopital Fleurimont	Sherbrooke	Quebec
Canada	Cape Breton Regional Hospital	Sydney	Nova Scotia
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	Vancouver Island Health Authority	Victoria	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29)	The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health.	Baseline, Months 12 and 24
Secondary	Change from Baseline in Annualized Relapse Rate	A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.	Baseline, Months 12 and 24
Secondary	Change from Baseline in Expanded Disability Status Scale (EDSS)	The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.	Baseline, Months 12 and 24
Secondary	Change from Baseline in Work Productivity and Activity Impairment	The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.	Baseline, Months 12 and 24
Secondary	Change from Baseline in EuroQol 5-Dimension (EQ-5D)	The EQ-5D is a self-administered questionnaire consisting of 5 sets of 3 questions pertaining to specific health states (i.e., mobility, self-care, pain, usual activities, anxiety), and a visual analog scale that records the respondent's self-rated health from 0 (worst imaginable health state) to 100 (best imaginable health state).	Baseline, Months 12 and 24
Secondary	Change from Baseline in Patient Global Assessment of Wellbeing Visual Analog Scale	Patient Global Assessment of Wellbeing measures quality of life on a 100 mm Visual Analog Scale (VAS) where 0 is the worst imaginable health state and 100 is the best imaginable health state.	Baseline, Months 12 and 24
Secondary	Percentage of participants with Clinical Disease-Free Status	Freedom from clinical disease activity is defined as the percentage of participants with no relapse and no EDSS progression, defined as a 1-point change from baseline. EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.	Baseline, Months 12 and 24